Phase I metabolites (organic acids) of gamma-hydroxybutyric acid-validated quantification using GC-MS and description of endogenous concentration ranges.
detection window
dihydroxybutyric acid
endogenous concentrations
gamma-hydroxybutyric acid
gas chromatography-mass spectrometry
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
31
03
2020
revised:
05
05
2020
accepted:
10
05
2020
pubmed:
18
5
2020
medline:
29
6
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
Gamma-hydroxybutyric acid (GHB) is a sedative drug used in drug-facilitated crimes. Its detection window is very short. GHB undergoes intensive phase I metabolism to organic acids (glycolic acid, succinic acid, dihydroxybutyric acids). These could be potential analytical targets to broaden the detection window. The aim of the present study was to enable the detection of endogenous levels of these metabolites in biological samples (blood and urine). A gas chromatographic-mass spectrometric method using liquid-liquid extraction and derivatization with N-methyl-N-tri-methylsilyltrifluoracetamide was developed for the quantification. Validation results were consistent with international guidelines, and the method was able to quantify endogenous levels of the substances in both urine and blood. Endogenous concentrations were shown to be <0.03-4.92 mg/L for glycolic acid, <0.03-1.28 mg/L for GHB, <0.28-18.1 mg/L for succinic acid, <0.12-1.38 mg/L for 2,4-dihydroxybutyric acid, and <0.13-2.59 mg/L for 3,4-dihydroxybutyric acid in serum samples of 101 volunteers. Urinary endogenous concentrations were shown to be 1.30-400 mg/L for glycolic acid, <0.03-1.94 mg/L for GHB, 1.17-2.73 mg/L for succinic acid, 0.72-26.2 mg/L for 2,4-dihydroxybutyric acid, and 1.88-122 mg/L for 3,4-dihydroxybutyric acid in urine samples of 132 volunteers. These endogenous concentrations represent a basis to which concentrations after the intake of GHB can be compared to in order to prove the intake of this substance.
Substances chimiques
Hydroxybutyrates
0
4-hydroxybutyric acid
30IW36W5B2
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1135-1143Informations de copyright
© 2020 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
Roth R, Giarman N. Natural occurrence of gamma-hydroxybutyrate in mammalian brain. Biochem Pharmacol. 1970;19:1087-1093.
Kam P, Yoong F. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia. 1998;53(12):1195-1198.
Busardo FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47-70.
Cash CD. Gammahydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev. 1994;18(2):291-304.
Carai MA, Colombo G, Brunetti G, et al. Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol. 2001;428(3):315-321.
Giarman N, Schmidt K. Some neurochemical aspects of the depressant action of γ-butyrolactone on the central nervous system. Br J Pharmacol Chemother. 1963;20(3):563-568.
Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3(4):433-IN8.
Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg. 1962;41(6):721-726.
Winters WD, Spooner CE. Various seizure activities following gamma-hydroxybutyrate. Int J Neuropharmacol. 1965;4(4):197-IN1.
Caputo F, Vignoli T, Tarli C, et al. A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health. 2016;13(3):290-295.
Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology. 1993;9(1):77-81.
Brown MA, Guilleminault C. A review of sodium oxybate and baclofen in the treatment of sleep disorders. Curr Pharm Des. 2011;17(15):1430-1435.
Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6(1):1-6.
Busardo F, Kyriakou C, Napoletano S, Marinelli E, Zaami S. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci. 2015;19(23):4654-4663.
Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB)-a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35(6):581-590.
Rossi R, Lancia M, Gambelunghe C, Oliva A, Fucci N. Identification of GHB and morphine in hair in a case of drug-facilitated sexual assault. Forensic Sci Int. 2009;186(1-3):e9-e11.
Drasbek KR, Christensen J, Jensen K. Gamma-hydroxybutyrate-a drug of abuse. Acta Neurol Scand. 2006;114(3):145-156.
Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21(12):1486-1513.
Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1, 4-butanediol (1, 4-BD). Drug Test Anal. 2011;3(7-8):417-425.
Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm. 2002;59(11):1067-1076.
Shima N, Miki A, Kamata T, Katagi M, Tsuchihashi H. Endogenous level and in vitro production of GHB in blood from healthy humans, and the interpretation of GHB levels detected in antemortem blood samples. J Health Sci. 2005;51(2):147-154.
Bertol E, Argo A, Procaccianti P, et al. Detection of gamma-hydroxybutyrate in hair: validation of GC-MS and LC-MS/MS methods and application to a real case. J Pharm Biomed Anal. 2012;70:518-522.
Pyo JS, Lee HS, Kwak J-H, Choe S. Determination of gamma-Hydroxybutyric acid in urine by solid phase extraction and gas chromatography-mass spectrometry. Anal Lett. 2016;49(2):217-225.
Wang X, Linnet K, Johansen SS. Development of a UPLC-MS/MS method for determining γ-hydroxybutyric acid (GHB) and GHB glucuronide concentrations in hair and application to forensic cases. Forensic Toxicol. 2016;34(1):51-60.
Wang S-M, Giang Y-S, Lu M-J, Kuo T-L. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by simultaneous extraction and chemical derivatization followed by GC-MS. Forensic Sci J. 2006;5(1):41-54.
Mehling L-M, Piper T, Spottke A, et al. GHB-O-β-glucuronide in blood and urine is not a suitable tool for the extension of the detection window after GHB intake. Forensic Toxicol. 2017;35(2):263-274.
Mehling L-M, Wang X, Johansen S-S, et al. Determination of GHB and GHB-b-O-glucuronide in hair of three narcoleptic patients-comparison between single and chronic GHB exposure. Forensic Sci Int. 2017;278:e8-e13.
Piper T, Mehling L-M, Spottke A, et al. Potential of GHB phase-II-metabolites to complement current approaches in GHB post administration detection. Forensic Sci Int. 2017;279:157-164.
Brown G, Cromby C, Manning N, Pollitt R. Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of α-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial β-oxidation. J Inherit Metab Dis. 1987;10(4):367-375.
Shinka T, Inoue Y, Ohse M, et al. Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography-mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B. 2002;776(1):57-63.
Prasad C, Napier MP, Rupar CA, Prasad C. Fumarase deficiency: a rare disorder on the crossroads of clinical and metabolic genetics, neurology and cancer. Clin Dysmorphol. 2017;26(2):117-120.
Jiang D, Geng H. Primary hyperoxaluria. N Engl J Med. 2017;376(15):e33.
Keyfi F, Lukacs Z, Varasteh A. A description of reference ranges for organic acids in urine samples from a pediatric population in Iran. Rep Biochem Mol Biol. 2017;6(1):40-50.
Hewlett TP, McMartin KE, Lauro AJ, Ragan FA. Ethylene glycol poisoning. The value of glycolic acid determinations for diagnosis and treatment. J Toxicol Clin Toxicol. 1986;24(5):389-402.
Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165(2-3):216-224.
Liu J, Deng Z, Zhu Z, et al. Determination of γ-hydroxybutyrate in human urine samples by ion exclusion and ion exchange two-dimensional chromatography system. J Chromatogr A. 2017;1528:35-40.
Fjeld B, Burns ML, Karinen R, Larssen B, Smith-Kielland A, Vindenes V. Long-term stability of GHB in post-mortem samples and samples from living persons, stored at -20 degrees C, using fluoride preservatives. Forensic Sci Int. 2012;222:47-51.
Chen M, Andrenyak DM, Moody DE, Foltz RL. Stability of plasma gamma-hydroxybutyrate determined by gas chromatography-positive ion chemical ionization-mass spectrometry. J Anal Toxicol. 2003;27:445-448.
Jones AW, Gladh SA, Windberg CN, Johansen SS. Stability of gamma-Hydroxybutyrate in blood samples from impaired drivers after storage at 4 degrees C and comparison of GC-FID-GBL and LC-MS-MS methods of analysis. J Anal Toxicol. 2015;39:294-299.
Beránková K, Mutnanska K, Balikova M. Gamma-hydroxybutyric acid stability and formation in blood and urine. Forensic Sci Int. 2006;161:158-162.
Busardo FP, Zaami S, Baglio G, et al. Assessment of the stability of exogenous gamma hydroxybutyric acid (GHB) in stored blood and urine specimens. Eur Rev Med Pharmacol Sci. 2015;19:4187-4194.
Elian AA. Determination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and blood. Forensic Sci Int. 2002;128(3):120-122.
Andresen H, Sprys N, Schmoldt A, Mueller A, Iwersen-Bergmann S. Gamma-hydroxybutyrate in urine and serum: additional data supporting current cut-off recommendations. Forensic Sci Int. 2010;200(1-3):93-99.
Erdmann F, Zandt D, Auch J, Schütz H, Weiler G, Verhoff M. Investigations concerning the threshold value between endogenous and exogenous GHB (liquid ecstasy). Archiv Fur Kriminologie. 2006;217(5-6):129-136.
Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int. 2003;133(1-2):9-16.
Kang S, Oh SM, Chung KH, Lee S. A surrogate analyte-based LC-MS/MS method for the determination of γ-hydroxybutyrate (GHB) in human urine and variation of endogenous urinary concentrations of GHB. J Pharm Biomed Anal. 2014;98:193-200.
Brailsford AD, Cowan DA, Kicman AT. Urinary γ-hydroxybutyrate concentrations in 1126 female subjects. J Anal Toxicol. 2010;34(9):555-561.
LeBeau MA, Miller ML, Levine B. Effect of storage temperature on endogenous GHB levels in urine. Forensic Sci Int. 2001;119(2):161-167.
Petersen IN, Tortzen C, Kristensen JL, Pedersen DS, Breindahl T. Identification of a new metabolite of GHB: gamma-hydroxybutyric acid glucuronide. J Anal Toxicol. 2013;37(5):291-297.
Walkenstein SS, Wiser R, Gudmundsen C, Kimmel H. Metabolism of γ-hydroxybutyric acid. Biochim Biophys Acta (BBA)-Gen Subj. 1964;86(3):640-642.
Roth RH, Giarman NJ. Preliminary report on the metabolism of gamma-BUTYROLACTONE and gamma-HYDROXYBUTYRIC acid. Biochem Pharmacol. 1965;14:177-178.
Möhler H, Patel A, Balazs R. Gamma-hydroxybutyrate degradation in the brain in vivo: negligible direct conversion to GABA. J Neurochem. 1976;27(1):253-258.
Lee C. Evidence for the β-oxidation of orally administered 4-hydroxybutyrate in humans. Biochem Med. 1977;17(3):284-291.
Gibson K, Hoffmann C, Hodson A, Bottiglieri T, Jakobs C. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics. 1998;29(01):14-22.
Palomino-Schätzlein M, Wang Y, Brailsford AD, et al. Direct monitoring of exogenous γ-hydroxybutyric acid in body fluids by nmr spectroscopy. Anal Chem. 2017;89(16):8343-8350.
Steuer AE, Raeber J, Steuer C, et al. Identification of new urinary gamma-hydroxybutyric acid markers applying untargeted metabolomics analysis following placebo-controlled administration to humans. Drug Test Anal. 2019;11(6):813-823.
Fell V, Lee C, Pollitt R. The occurrence of (S)-3, 4-dihydroxybutyrate in human blood and urine. Biochem Med. 1975;13(1):40-45.
Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS ONE. 2013;8(9):e73076.
Zhou Y, Song R, Ma C, et al. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method. Oncotarget. 2017;8(13):20719-20728.
Nordmann J, Nordmann R. Organic acids in blood and urine. In: Advances in Clinical Chemistry. Amsterdam, Netherlands: Elsevier; 1961;4:53-120.
Asano K, Miyamoto I, Matsushita T, et al. Succinic acidemia: a new syndrome of organic acidemia associated with congenital lactic acidosis and decreased NADH-cytochrome c reductase activity. Clin Chim Acta. 1988;173(3):305-312.